New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2013
16:13 EDTSGENSeattle Genetics reports Q4 EPS (9c), consensus (11c)
Reports Q4 revenue $63.9M, consensus $57.21M.
News For SGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 10, 2015
07:21 EDTSGENExpert upbeat on Seattle Genetics Adcetris, says RBC Capital
After meeting with an expert, RBC Capital reports that he believes that off-label use of Seattle Genetics' Adcetris is increasing across a variety of indications. He believes that Adcetris is approvable and has a better chance of becoming a front-line treatment than competing drugs. The firm keeps a $50 price target and Outperform rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use